Investigating Safety and Efficacy of L9LS Monoclonal Antibodies in Western Kenya
COVID-19 Response
Partners Needed in the Coronavirus Response
In January 2020, the Centers for Disease Control and Prevention (CDC) requested the CDC Foundation activate our Emergency Response Fund to provide support to rapidly emerging response needs related to COVID-19. Support from individuals and organizations provides much needed funding to meet response needs where federal and state funding is not available or available quickly enough to meet the need.
Funds raised by the CDC Foundation through our Emergency Response Fund are being used to meet fast-emerging needs identified by CDC and public health authorities to help respond to the public health threat posed by this virus. These include additional support for state and local health departments, support for the global response, logistics, communications, data management, personal protective equipment, critical response supplies and more.
Learn how your contributions are making an impact.
For more information on how you can partner with the CDC Foundation, please contact Laura Croft, vice president for advancement, at 404.523.1788 or lcroft@cdcfoundation.org.
Integrated Serosurveillance Center and Serologic Surveillance in Nigeria
Many low- and middle-income countries lack the data necessary to fully describe disease threats in their countries and monitor the impact of public health efforts to prevent and control disease.
Serosurveillance—which involves monitoring the presence or absence of antibodies or proteins in the blood serum of a population—provides an objective biological measure for estimating population susceptibility, exposure and immunity. Serologic data are increasingly used to guide public health policy and strategy, from support of vaccine introduction to verification of disease elimination.
Currently, serosurveillance is often focused on a single disease. Integrated serosurveillance (multi-disease serologic surveillance) is a cost-effective approach that can dramatically scale up the availability of data for public health action, including for diseases currently unmonitored.
CDC has developed an approach to integrated serosurveillance for multiple diseases of public health importance using a multiplex bead assay platform. The platform can simultaneously measure up to 100 different disease-specific markers from a single dried blood spot, creating novel opportunities to establish integrated nationally representative serosurveillance programs. If well implemented, integrated serosurveillance could increase the quality and breadth of data available for infectious disease modeling and efforts to describe transmission risks. Data collected through integrated serosurveillance can also inform implementation of prevention opportunities across multiple diseases.
But, implementation of integrated serosurveillance requires coordination of subject matter expertise and ongoing technical assistance to ensure generation of high-quality data for public health decision making. CDC’s vision is to expand capacity to implement this approach around the globe where data from integrated serosurveillance could drive critical aspects of public health programs.
In Nigeria, the Nigeria CDC has identified integrated serosurveillance as a priority for generating high-quality supplemental information to augment the existing surveillance network, and for their overall public health response. With funding from the Bill and Melinda Gates Foundation, the CDC Foundation is working with CDC and other partners to strengthen the capacity of Nigeria’s National Reference Laboratory to conduct integrated serosurveillance multiplex bead assay technology. The support is part of a multi-partner effort that includes multiple CDC programs, donors and partners.
As results are available, CDC is working with the Nigeria CDC and government partners to analyze multiplex testing data and apply results to advance public health programs. In addition, CDC is applying lessons learned from Nigeria and previous projects to develop the tools and technical assistance capacity needed to accelerate the implementation of integrated serosurveillance in other countries.
The AMR Fund
Antimicrobial resistance (AMR) jeopardizes the progress made in combating infectious disease, putting efforts to modernize health care at risk.
AMR is a unique public health challenge as it involves dozens of different pathogens that are constantly evolving and transferring new mechanisms of resistance. AMR is a One Health issue, recognizing that the health of people is connected to the health of animals and the environment. Governments, businesses and philanthropies can work together to address the health threat of AMR.
The CDC Foundation has established an AMR Fund to assist CDC and its partners to continue making meaningful progress across the spectrum of AMR: from improving antibiotic use, including access to lifesaving drugs, to investing in innovative ways to prevent and treat these infections.
The AMR Fund will mobilize financial support and progress in the five areas associated with the U.S Department of Health and Human Services and CDC's AMR Challenge:
- Tracking and data—Sharing data and improving data collection to stay ahead of antibiotic resistance and prevent infections.
- Infection prevention and control—Preventing infections and reducing the spread of germs.
- Antibiotic use–Improving the use of antibiotics, including ensuring access.
- Environment and sanitation—Keeping antibiotics and antibiotic-resistant threats from entering the environment.
- Vaccines, therapeutics and diagnostics—Developing and improving access to vaccines, therapeutics and diagnostics for better prevention, treatment and detection.
Ebola Outbreak Response in DRC Demonstrates Importance of Global Health Security
2018-07-13
Read morePagination
- You're on Page 1
- Next page